Elsevier

Osteoarthritis and Cartilage

Volume 8, Issue 5, September 2000, Pages 335-342
Osteoarthritis and Cartilage

Regular Article
A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon®) as a structure modifying therapy in osteoarthritis of the hip and knee

https://doi.org/10.1053/joca.1999.0307Get rights and content
Under an Elsevier user license
open archive

Abstract

Objective To determine the structure (disease) modifying effect of a glycosaminoglycan polypeptide association complex (GP-C; Rumalon®) in patients with knee and hip osteoarthritis (OA).

Methods Double-blind, randomized, placebo-controlled five-year study. Primary assessment criterion was change in radiographic joint space width between baseline and follow-up at 5 years. Secondary outcome criteria included Lequesne algofunctional index (LAI), pain on passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of placebo or GP-C 2 ml intramuscularly in 5 years (two courses each year). Each course included 15 injections administered twice weekly.

Results There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-C treated groups were comparable as to sex, age, duration of disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37±0.08 (mean±standard deviation) mm for GP-C and 0.42±0.08 mm for placebo groups (P=0.68). Hip joint space at 5 years decreased 0.21±0.08 mm for GP-C and 0.22±0.08 mm for placebo groups (P=0.53). In a subset of patients with hip OA, Kellgren–Lawrence≥2 and JSW≥1 mm, there was a trend in favor of GPC for lower joint space narrowing in 5 years (P=0.11). In addition, there were no statistical differences between the treatment groups in LAI, pain on passive motion and consumption of NSAIDs. Side-effects after GP-C (14.5%) were rare, mild and not more frequent than in the placebo group (15%).

Conclusion We were not able to demonstrate a structure modifying effect of GP-C in OA of the hip or knee. Radiographic progression of OA in both knee and hip OA was lower than expected in both study groups.

Keywords

Osteoarthritis, X-ray progression, Rumalon®, Disease modification, Knee, Hip

Cited by (0)

f1

Address correspondence to: Assoc. Prof. Karel Pavelka, M.D., Institute of Rheumatology, Na slupi 4, 128 50 Praha 2, Prague, Czech Republic. Tel: 004202 292452; Fax: 004202 4914451; E-mail:[email protected]